NCT05320029

Brief Summary

To evaluate whether the anastomosis success rate of the main effectiveness evaluation indexes is not inferior to the similar products produced by Johnson \& Johnson when the Fengh Disposable Powered Articulating Endoscopic Linear Cutter Stapler Used for Gastrointestinal Tissue Cutting and Anastomosis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
164

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 30, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 11, 2020

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 31, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 11, 2022

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

November 24, 2023

Completed
Last Updated

December 14, 2023

Status Verified

November 1, 2023

Enrollment Period

1.5 years

First QC Date

March 31, 2022

Results QC Date

February 13, 2023

Last Update Submit

November 23, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Anastomosis Success

    The transection and anastomosis of lung tissues are performed during the operation. The device is withdrawn after successful triggering. The cutting staple line is carefully checked for integrity, air leakage and bleeding. Anastomosis is considered as successful if all anastomotic rings are intact without leakage or bleeding, otherwise it is considered as failure. If necessary, the gas injection method is used to inspect whether there is bubble overflow at anastomotic stoma. If there is no bubble overflow, it is recorded as successful anastomosis; if there is obvious bubble overflow, it is recorded as anastomosis failure.

    During surgery

Study Arms (2)

Disposable Powered Articulating Endoscopic Linear Cutter Stapler

EXPERIMENTAL

Disposable Powered Articulating Endoscopic Linear Cutter Stapler

Device: Disposable Powered Articulating Endoscopic Linear Cutter Stapler

ECHELON Flex Powered Articulating Endoscopic Linear Cutters

ACTIVE COMPARATOR

ECHELON Flex Powered Articulating Endoscopic Linear Cutters

Device: ECHELON Flex Powered Articulating Endoscopic Linear Cutters

Interventions

Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment

Disposable Powered Articulating Endoscopic Linear Cutter Stapler

Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment

ECHELON Flex Powered Articulating Endoscopic Linear Cutters

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The subjects are 18 \~ 75 years old, regardless of gender:
  • Subjects need to use a linear stapler for gastrointestinal tissue cutting and anastomosis:
  • The subject or his legal representative can understand the purpose of the study and show sufficient compliance with the study protocol And sign informed consent.

You may not qualify if:

  • The subject plans to perform emergency gastrointestinal surgery:
  • Subjects with moderate malnutrition (BML \< 17kg / m2) and severe anemia (HB \< 60g / L):
  • Subject BMI 228kg / m2;
  • Subject platelet (PLT) \< 60x 109 / L or international normalized ratio (INR) \> 1.5;
  • Subject forced expiratory volume per second (FEV1) / expected value ≤ 50%, or forced expiratory volume per second (FEV1) / forced vital capacity (FCV) \< 60%;
  • Subject's cardiac ejection fraction ≤ 50%;
  • Have important organ failure or other serious diseases (e.g. preoperative subject aspartate amino acid) Transferase (AST), or alanine aminotransferase (ALT), or serum creatinine (SER) exceeds normal values
  • Upper limit 3 times and above: subjects with fasting blood glucose value \> 10.0mmol/l before operation:
  • The subjects were pregnant or lactating women; Page 16 of 53 Version No.: 1.1/version date 20190125 Clinical trial on the efficacy and safety of linear cutting stapler and components for disposable electric endoscopy for cutting and anastomosis of gastrointestinal tissue
  • Subjects participated in clinical trials of other drugs or devices within 3 months before the trial;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Disposable Powered Articulating Endoscopic Linear Cutter Stapler

Jiangyin, Jiangsu, 214437, China

Location

MeSH Terms

Conditions

Gastrointestinal Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal Diseases

Results Point of Contact

Title
Jiao Liu
Organization
Fengh Medical Co., Ltd.

Study Officials

  • Qing Ni

    First People's Hospital of Yangzhou

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
A test method in which subjects are not told whether they are a trial device or a control device in order to control intentional or unintentional bias in the course of a clinical trial and in the interpretation of results
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Patients randomized to the trial group and the control group will not cross use the product
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2022

First Posted

April 11, 2022

Study Start

August 30, 2018

Primary Completion

February 11, 2020

Study Completion

January 20, 2022

Last Updated

December 14, 2023

Results First Posted

November 24, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Participants can only see the results of CT, blood routine, coagulation function, fasting blood glucose, fecal occult blood test, cardiac ultrasound, pulmonary function and gastrointestinal angiography, and the other results are not shared

Locations